Aldeyra Therapeutics, Inc. (ALDX)

Compare

5.32

-0.15

(-2.74%)

At close: 4:00:01 PM EDT

5.05

-0.27

(-5.16%)

After hours: 5:22:28 PM EDT

High Growth Tech Stocks To Watch In The US March 2025

Over the last 7 days, the United States market has experienced a 4.6% drop, yet it remains up by 8.8% over the past year with earnings projected to grow by 14% annually. In this context of fluctuating performance and promising growth forecasts, identifying high-growth tech stocks involves focusing on companies with strong innovation potential and robust financial health that can capitalize on these market conditions.

Simply Wall St. 22 days ago

BLND

BLKB

ALDX
-2.74%
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

LEXINGTON, Mass., March 10, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.

Business Wire 23 days ago

ALDX
-2.74%
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

LEXINGTON, Mass., February 04, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. The conference is being conducted virtually on February 11, 2025.

Business Wire last month

ALDX
-2.74%
Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology […]

Insider Monkey 2 months ago

ALDX
-2.74%
3 US Penny Stocks With Market Caps Over $80M To Watch

As the U.S. stock market concludes a strong year on a weak note, with major indices like the Dow experiencing significant monthly losses, investors are reflecting on opportunities within various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential growth despite their somewhat outdated label. By focusing on companies that exhibit solid financial health and promising prospects, investors can uncover potential value in...

Simply Wall St. 2 months ago

ALDX
-2.74%
KNDI

ANL
High Growth Tech Stocks To Watch In December 2024

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility.

Simply Wall St. 3 months ago

AKBA
+1.05%
ALDX
-2.74%
INFN
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.

Zacks 3 months ago

ALDX
-2.74%
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

LEXINGTON, Mass., December 02, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024.

Business Wire 3 months ago

ALDX
-2.74%
Top US Penny Stocks To Watch In November 2024

As the U.S. stock market shows signs of a modest recovery, with major indices inching higher ahead of key earnings reports, investors are keenly observing smaller sectors for potential opportunities. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as they often represent emerging companies that could offer growth at lower entry points. This article explores three penny stocks that stand out for their financial resilience and potential to provide compelling...

Simply Wall St. 4 months ago

HYLN

ALDX
-2.74%
ADV
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.

Zacks 4 months ago

ALDX
-2.74%
ABBV
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

LEXINGTON, Mass., November 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for

Business Wire 4 months ago

ALDX
-2.74%
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

LEXINGTON, Mass., November 14, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024.

Business Wire 4 months ago

ALDX
-2.74%
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?

Here is how BellRing Brands (BRBR) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks 4 months ago

BRBR

ALDX
-2.74%
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

LEXINGTON, Mass., October 31, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.

Business Wire 4 months ago

ALDX
-2.74%
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

LEXINGTON, Mass., October 03, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes pr

Business Wire 5 months ago

ALDX
-2.74%
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass., September 05, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference.

Business Wire 6 months ago

ALDX
-2.74%
High Growth Tech Stocks To Watch In The United States

Over the last 7 days, the market has dropped 1.9%, but it is up 21% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks that can capitalize on these favorable conditions is crucial for investors looking to maximize their returns.

Simply Wall St. 6 months ago

ALDX
-2.74%
CSGS

PRGS
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory

We came across a bullish thesis on Aldeyra Therapeutics Inc (ALDX) on ValueInvestorsClub by MrStingy. In this article we will summarize the bulls’ thesis on ALDX. Aldeyra Therapeutics shares were trading at $4.15 when this thesis was published, vs. closing price of $5.38 on Aug 29. Aldeyra Therapeutics, a biotechnology company specializing in the development […]

Insider Monkey 6 months ago

ALDX
-2.74%
ABBV
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint

The investigational new drug candidate Reproxalap is intended for the treatment of dry eye disease and allergic conjunctivitis.

Clinical Trials Arena 7 months ago

ALDX
-2.74%
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

LEXINGTON, Mass., August 08, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxa

Business Wire 7 months ago

ALDX
-2.74%

Performance Overview

Return	ALDX	S&P 500 (^GSPC)
YTD	+6.71%	-3.58%
1-Year	+50.00%	+8.94%
3-Year	+13.06%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aldeyra Therapeutics, Inc. (ALDX)

High Growth Tech Stocks To Watch In The US March 2025

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

3 US Penny Stocks With Market Caps Over $80M To Watch

High Growth Tech Stocks To Watch In December 2024

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Top US Penny Stocks To Watch In November 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

High Growth Tech Stocks To Watch In The United States

Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory

Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Performance Overview